|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Heterogeneity of aberrant immunoglobulin expression in cancer cells显示文摘Accumulating evidence has shown that immunoglobulin(Ig)is‘unexpectedly’expressed by epithelial cancer cells and that it can promote tumor growth.The main purpose of this study was to explore the components of the cancerous Ig and its possible function.The presence of cancerous Ig in the Golgi apparatus was confirmed by immunofluorescence,indirectly suggesting that the cancerous Ig was processed and packaged in cancer cells.Western blot analysis and ELISA results indicated that cancer cells produced membrane Ig and secreted Ig into the supernatant fraction.The cancerous Ig consists of an a heavy chain and a k light chain.Finally,by analyzing the Ig components pulled down by protein A beads,the cancerous Ig was found to be structurally distinct from normal Ig.The cancerous Ig was truncated or aberrant.Although the underlying mechanism that causes the abnormalities has not been determined,our current discoveries strengthen our previous findings and promise fruitful future explorations. | Duosha Hu Zhi Duan Ming Li Yiqun Jiang Haidan Liu Hui Zheng Lili Li Ann M Bode Zigang Dong Ya Cao | 2011 | Cellular & Molecular Immunology2011，8，6： | 5 |
| 2 | 利拉鲁肽与格列美脲在单药治疗2型糖尿病中的比较(LEAD-3 Mono):一项随机、双盲、平行分组、52周的Ⅲ期临床试验显示文摘背景 2型糖尿病新的治疗策略,需要针对胰岛素-葡萄糖的相互作用,且同时要降低体重增加和发生低血糖的风险。本文作者旨在调查利拉鲁肽单药治疗2型糖尿病的安全性与有效性。
方法 采用双盲、双模拟、治疗一对照、平行分组的研究,746例早期2型糖尿病患者被随机分配到1次/d利拉鲁肽组[1.2mg(n=251)或1.8mg(n=247)]或格列美脲8mg组(n=248),分别治疗52周。主要结局指标为糖化血红蛋白(HbA1c)的改变程度。采用意向性治疗进行分析。该试验在ClinicalTrials.gov网站的注册编码为NTC00294723.
结果52周时,格列美脲组HbA,。下降了0.51%(s=1.20),而利拉鲁肽1.2mg组下降了0.84%(s=1.23)(差值为-0.33.95%CI-0.53~-0.13;P=0.0014),利拉鲁肽1.8mg组下降了1.14%(S=1.24)(差值为-062,95%CI-0.83—-0.42;P〈0.0001)。利拉鲁肽1.2mg组和1.8mg组各有5例和1例患者因呕吐停止治疗,而格列美脲组未出现这种情况。
结论 利拉鲁肽作为2型糖尿病的初始治疗药物安全有效,与格列美脲相比更能降低HbA1c以及体重、血压和低血糖的发生率。 | Alan Garber Robert Henry Robert Rather Pedro A Garcia-Hernandez Hiromi Rodriguez-Pattzi Israel Olvero-Alvarez Paula M Hale, Milan Zdravkovic Bruce Bode 邓斌(译) | 2009 | 世界临床医学2009，，6： | 5 |
| 3 | Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial显示文摘 | Alan Garber Robert Henry Robert Ratner Pedro A Garcia-Hernandez Hiromi Rodriguez-Pattzi Israel Olvera-Alvarez Paula M Hale Milan Zdravkovic Bruce Bode | 2009 | The Lancet2009，，9662： | 2 |
| 4 | Rab3D and annexin A2 play a role in regulated secretion of vWF,but not TPA,from endothelial cells显示文摘 | Knop M AareskjoldE Bode G | 2004 | EMBO J2004，23，15： | 1 |
| 5 | Characterization of conditions for the primary culture of human small intestinal epithelial cells显示文摘 | ALDHOUS M C SHMAKOV A N BODES J | 2001 | Clin Exp Immunol2001，125，1： | 1 |
| 6 | Progress in the catalysis of the upgrading of petroleum residue: A review of 25 years of R&D on Shell's residue hydroconversion technology显示文摘 | OELDERIK J M SIE S T BODE D | 1989 | Appl Catal1989，47，1： | 1 |
| 7 | Biotransformation of metamitron by human P450 expressed in transgenic tobacco cell cultures 显示文摘 | Bode M Haas M Faymonville T Thiede B Schuphan I Schmidt B | 2006 | Journal of Environmental Science and Health2006，41，3： | 1 |
| 8 | Chemo-enzymatic synthesis of the chiral side-chain of statins:application of an alcohol dehydrogenase catalyzed ketone reduction on a large scale 显示文摘 | Wolberg M Filho M V Bode S | 2008 | Bioprocess Biosyst Eng2008，31，： | 1 |
| 9 | In vivo and in vitro metabolism of trans-resveratrol by human gut micro- biota显示文摘 | Bode L M Bunzel D Huch M | 2013 | The American Journal of Clinical Nutrition2013，97，2： | 1 |
| 10 | Correction of the bleeding time with lyophilized platelet infusions in dogs on cardiopulmonary bypass 显示文摘 | BODE A P LUST R M READ M S | 2008 | Clin Appl Thromb Hemost2008，14，： | 1 |
| 11 | MacMolPlt: a graphical user interface for GAMESS显示文摘 | Bode B M Gordon M S | 1998 | Journal of Molecular Graphics and Modelling1998，16，3： | 1 |
| 12 | E 6 ]- Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase 显示文摘 | JEONG C H BODE A M PUGLIESE A | 2009 | Cancer Res2009，69，13： | 1 |
| 13 | Slimflor and slimdek construction: European developments 显示文摘 | Lawson R M Bode H Brekelmans J W P M | 1999 | The Structural Engineer1999，77，8： | 1 |
| 14 | Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin:Implications for the inhibition of factor Xa, tPA and Urokinase 显示文摘 | Renatus M Bode W Huber R | 1998 | J Med Chem1998，41，： | 1 |
| 15 | Characterization of conditions for the primary culture of human small intestinal epithelial cells显示文摘 | ALDHOUS M C SHMAKOV A N BODE J | 2001 | Clin Exp Immunol2001，125，1： | 1 |
| 16 | 显示文摘 | Fischer R Schmitt M Bode JG | 2001 | Gastroenterology2001，120，5： | 1 |
| 17 | Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane a2 as a new player显示文摘 | Bode M Mackman N | 2014 | Vascul Pharmacol2014，62，2： | 1 |
| 18 | An overview of the municipal waste incineration industry in Asia and the former Soviet Union显示文摘 | TIMOTHY R CROCKETT BODE M A | 1996 | Journal of Hazardous Material1996，47，： | 1 |
| 19 | The transgeneticist's toolbox:Novel methods for the targeted modification of eukaryotic genomes显示文摘 | Bode J Schlake T Iber M | 2000 | Biol Chem2000，381，： | 1 |
| 20 | The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects 显示文摘 | BODE A M DONG Z G | 2002 | Cri Rev Oncol Hematol2002，42，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员